Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
July 20, 2017 at 14:51 PM EDT
This is the second major acquisition of a bioterrorism-related countermeasures drug in two weeks for the Gaithersburg-based company.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|